ISRCTN19548431已完成不适用
Effects of metformin on cardiovascular risk factors in prepubertal children born small for gestational age without postnatal catch-up growth, currently treated with growth hormone: a prospective randomised clinical trial
Hospital Sant Joan de Deu (Spain)0 个研究点目标入组 64 人开始时间: 2010年5月27日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Prepubertal boys and girls between 7- 10 years old
- •2. SGA: weight less than or equal to -2 SD for gestational age and gender
- •3. Full-term pregnancy (gestational age between 37 - 42 weeks)
- •4. Caucasian origin
- •5. Prepubertal (Tanner I)
- •6. GH treatment during the previous 1 - 3 years and currently on treatment at the time of the study
- •7. Positive response to GH treatment with a 1 SD increase in height velocity
排除标准
- •1. Known causes of SGA: congenital infections, genetic syndromes
- •2. Drug and/or alcohol consumption
- •3. During the study: liver or kidney disorders or oncological disease
- •4. Thyroid hormone disorders
- •5. Obesity (body mass index [BMI] greater than or equal to + 2SD for age), glucose intolerance or type 2 diabetes
- •6. Treatment with glucocorticoids, sex hormones or drugs that could affect glucose tolerance
- •7. Infectious or inflammatory symptoms in the 15 days prior to sample collection
研究者
相似试验
进行中（未招募）
1 期
Effects of metformin treatment on myocardial efficiency in patients with heart failureEUCTR2015-002767-42-DKAarhus University Hospital36
Unknown
4 期
Metformin in Postmenopausal Women With Metabolic SyndromeMetabolic SyndromeNCT01342744Mahidol University40
进行中（未招募）
1 期
The effect of metformin on weight and cardiovascular risk markers in abdomenally obese subjects with impaired fasting glucose previously treated for 12 months with either rimonabant or placebo - Use of Metformin following weight loss and improvement in CV riskImpaired fasting glucoseMedDRA version: 9.1Level: LLTClassification code 10056997Term: Impaired fasting glucoseEUCTR2008-004497-40-GBHull and East Yorkshire Hospitals NHS Trust
尚未招募
2 期
Cardioprotective Effect of Metformin on the level of micro RNAs, mir-222, mir-195, mir-21a, in type 1 diabetes patientsCondition 1: Type 1 diabetes. Condition 2: Cardiovascular disease.IRCT20200217046520N1Shahid Beheshti University of Medical Sciences28
已完成
2 期
Evaluation of the effect of metformin in STEMI patients treated with thrombolytic therapyIRCT20111206008307N34Tabriz University of Medical Sciences80